All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Patients with newly diagnosed multiple myeloma (NDMM) who are eligible for transplant and have high-risk cytogenetics traditionally have a poor prognosis.1 To improve this, different treatment combinations have been trialed with some success, such as carfilzomib, lenalidomide, and dexamethasone (KRd) in the FORTE trial and adding daratumumab (dara) to frontline therapy as in the CASSIOPEIA and GRIFFIN trials. In addition, tandem stem cell transplants have improved the outcome of these high-risk patients with NDMM.1
In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with NDMM eligible for transplant; Touzeau1 presented the results of this trial at the European Hematology Association (EHA) 2022 Congress, which we are pleased to summarize here.
The dosing schedule and study design for the IFM2018-04 phase II trial (NCT03606577) are shown in Figure 1.
Inclusion criteria:
Endpoints:
Figure 1. Study design*
ASCT, autologous stem cell transplant; cyclo G-CSF, cyclophosphamide and granulocyte-colony stimulating factor; d, dexamethasone; dara, daratumumab; IV, intravenous; K, carfilzomib; Mel, melphalan; R, lenalidomide.
*Adapted from Touzeau.1
†Dara 16 mg/kg IV every 8 weeks + R 10 mg 21/28 days.
The median age of patients included in this trial was 57 years (range, 38−65 years) and the majority (94%) had an ECOG PS of 0−1. High-risk cytogenetics were present in all patients, with the most common being a t(4;14) translocation. In total, 68% of patients had two cytogenetic abnormalities (Table 1).
Table 1. Patient baseline characteristics and treatment disposition*
Characteristic, % (unless otherwise stated) |
Total (N = 50) |
---|---|
ISS score |
|
Stage 1 |
42 |
Stage 2 |
34 |
Stage 3 |
24 |
R-ISS score |
|
Stage 2 |
76 |
Stage 3 |
24 |
High-risk cytogenetics |
100 |
17p depletion |
40 |
t(4;14) |
52 |
t(14;16) |
20 |
1q gain |
50 |
Two high-risk cytogenetic abnormalities |
68 |
Treatment disposition |
|
Ongoing |
72 |
Consolidation |
22 |
ASCT #2, n |
1 |
Maintenance |
48 |
Discontinued |
28 |
Progressive disease, n |
2 |
Adverse event, n |
4 |
Withdrawal, n |
2 |
Stem cell collection failure, n |
6 |
ASCT, autologous stem cell transplantation; ECOG PS, Eastern Cooperative Oncology Group performance status; R-ISS, revised International Staging System. |
Treatment-emergent adverse events (TEAEs) are shown in Figure 2. No new safety signals were observed in this trial for dara-KRd + tandem transplant. The most common hematologic TEAE was neutropenia, with infection and gastrointestinal disorders being the most frequently observed non‑hematologic TEAEs.
There were two cases of patients with AEs leading to discontinuation (one case of COVID-19 infection and one case of tumor lysis syndrome). Grade III/IV infections occurred in three patients:
Figure 2. Treatment-emergent adverse events*
GI, gastrointestinal; TEAE, treatment-emergent adverse events.
*Adapted from Touzeau.1
During the first round of stem cell collection, failure occurred in six patients. In the patients in which collection was successful, the median CD34+ cell count was 6.1 × 106/kg (range, 0−16 × 106/kg).
As a result of this failure, the protocol was amended to collect stem cells after Cycle 3. Following this change, stem cell collection was successful in 21 patients and the median CD34+ cell collection achieved was 8.3 × 106/kg (range, 4.7−26 × 106/kg).
Measurable residual disease (MRD) was measured by next-generation sequencing with a threshold of 10−5. MRD negativity rate was 62%. The response to treatment is shown in Figure 3. Complete response/stringent complete response rate was 31% and the very good partial response or better rate was 91%.
Figure 3. Response rate*
CR, complete response; ORR, overall response rate; PR, partial response; sCR, stringent CR; VGPR, very good partial response.
*Adapted from Touzeau.1
Median follow-up was 19.4 months and the survival outcomes for patients with NDMM are shown in Table 2. At all timepoints, median PFS and OS were >90%.
Table 2. Survival outcomes at 12 months and 18 months*
Outcome, % (range) |
N = 50 |
---|---|
PFS |
|
12 months |
96 (90−100) |
18 months |
92 (84−100) |
OS |
|
12 months |
96 (90−100) |
18 months |
96 (90−100) |
OS, overall survival; PFS, progression-free survival. |
The results of the IFM-2018-04 trial in high-risk transplant-eligible patients with NDMM show that the quadruplet of dara-KRd + tandem transplant resulted in PFS and OS rates >90% at 18 months. An MRD-negativity rate of 62% was achieved with dara-KRd + tandem transplant, which was the same as the MRD-negative rate of 62% achieved in the FORTE trial with KRd and single transplant. These results are consistent with those achieved in the GMMG concept trial of isatuximab + KRd in high‑risk patients. To confirm both the efficacy and feasibility of this treatment combination and sequencing, a longer follow-up is required.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox